Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2078-2082

  Chilton, C H ^a   Freeman, J ^b   Baines, S D ^c   Crowther, G S ^a   Nicholson, S ^a   Wilcox, M H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Adherence; Outgrowth inhibition; Recurrence

Indexed keywords

METRONIDAZOLE; ORITAVANCIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG MONITORING; DRUG SCREENING; NONHUMAN; PHASE CONTRAST MICROSCOPY; POLYMERASE CHAIN REACTION; SPORE GERMINATION; STAPHYLOCOCCUS AUREUS;

ADHERENCE; OUTGROWTH INHIBITION; RECURRENCE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; GLYCOPEPTIDES; MICROBIAL VIABILITY; MICROSCOPY, PHASE-CONTRAST; SPORES, BACTERIAL; TIME FACTORS;

EID: 84882685517     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt160     Document Type: Article

References (23)

1. Freeman J, Wilcox MH. Antibiotics and Clostridium difficile. Microbes Infect 1999; 1: 377-84.
2. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-8.
3. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
4. Cornely OA, Miller MA, Louie TJ et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 Suppl 2: S154-61.
5. Nakamura S, Yamakawa K, Izumi J et al. Germinability and heatresistance of spores of Clostridium difficile strains. Microbiol Immunol 1985; 29: 113-8.
6. Maillard JY. Innate resistance to sporicides and potential failure to decontaminate. J Hosp Infect 2011; 77: 204-9.
7. Gerding DN, Johnson S, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459-77.
8. Vonberg RP, Kuijper EJ, Wilcox MH et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14: 2-20.
9. O'Connor R, Baines SD, Freeman J et al. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother 2008; 62: 762-5.
10. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
11. Chilton CH, Freeman J, Crowther GS et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012; 67: 2434-7.
12. Freeman J, Marquis M, Crowther GS et al. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. J Antimicrob Chemother 2012; 67: 2919-26.
13. Stringer SC, Webb MD, George SM et al. Heterogeneity of times required for germination and outgrowth from single spores of nonproteolytic Clostridium botulinum. Appl Environ Microbiol 2005; 71: 4998-5003.
14. Clostridium difficile network for England and Northern Ireland. CDRN annual report 2010/2011. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317133396963 (18 February 2013, date last accessed).
15. Baines SD, O'Connor R, Fawley WN et al. Activity of metronidazole, vancomycin and oritavancin against epidemic C. difficile spores. In: Programs and Abstracts of the Forty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL 2007, p. E-1627a. American Society for Microbiology, Washington, DC.
16. Chilton CH, Freeman J, Crowther GS et al. Decreased Clostridium difficile spore viability following oritavancin exposure. In: Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases, London 2012. Abstract P1441, p. 132. European Society of Clinical Microbiology and Infectious Diseases, Basal, Switzerland.
17. Allen CA, Babakhani F, Sears P et al. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother 2013; 57: 664-7.
18. Rayman MK, Aris B, Hurst A. Nisin: a possible alternative or adjunct to nitrite in the preservation of meats. Appl Environ Microbiol 1981; 41: 375-80.
19. Chan WC, Leyland M, Clark J et al. Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. FEBS Lett 1996; 390: 129-32.
20. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
21. Arhin FF, Sarmiento I, Belley A et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 2008; 52: 1597-603.
22. Wilcox MH, Winstanley TG, Spencer RC. Binding of teicoplanin and vancomycin to polymer surfaces. J Antimicrob Chemother 1994; 33: 431-41.
23. Belley A, Neesham-Grenon E, McKay G et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009; 53: 918-25.